APA (7th ed.) Citation

Grisham, R., Monk, B. J., Van Nieuwenhuysen, E., Moore, K. N., Fabbro, M., O'Malley, D. M., . . . Banerjee, S. (2025). GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. International journal of gynecological cancer, 35(11), 101832. https://doi.org/10.1136/ijgc-2024-005919

Chicago Style (17th ed.) Citation

Grisham, Rachel, et al. "GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A Phase 3, Randomized Trial Evaluating Avutometinib Plus Defactinib Compared with Investigator's Choice of Treatment in Patients with Recurrent Low Grade Serous Ovarian Cancer." International Journal of Gynecological Cancer 35, no. 11 (2025): 101832. https://doi.org/10.1136/ijgc-2024-005919.

MLA (9th ed.) Citation

Grisham, Rachel, et al. "GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A Phase 3, Randomized Trial Evaluating Avutometinib Plus Defactinib Compared with Investigator's Choice of Treatment in Patients with Recurrent Low Grade Serous Ovarian Cancer." International Journal of Gynecological Cancer, vol. 35, no. 11, 2025, p. 101832, https://doi.org/10.1136/ijgc-2024-005919.